OXYBUTYNIN

/static/temp/default.svg Search structure
Trade Names
Synonyms
Status
Molecule Category Free-form
ATC G04BD04
UNII K9P6MC7092
EPA CompTox DTXSID0023406

Structure

InChI Key XIQVNETUBQGFHX-UHFFFAOYSA-N
Smiles CCN(CC)CC#CCOC(=O)C(O)(c1ccccc1)C1CCCCC1
InChI
InChI=1S/C22H31NO3/c1-3-23(4-2)17-11-12-18-26-21(24)22(25,19-13-7-5-8-14-19)20-15-9-6-10-16-20/h5,7-8,13-14,20,25H,3-4,6,9-10,15-18H2,1-2H3

Physicochemical Descriptors

Property Name Value
Molecular Formula C22H31NO3
Molecular Weight 357.49
AlogP 3.34
Hydrogen Bond Acceptor 4.0
Hydrogen Bond Donor 1.0
Number of Rotational Bond 7.0
Polar Surface Area 49.77
Molecular species BASE
Aromatic Rings 1.0
Heavy Atoms 26.0

Bioactivity

Mechanism of Action Action Reference
Muscarinic acetylcholine receptor M2 antagonist ANTAGONIST ISBN PubMed PubMed PubMed PubMed
Protein: Muscarinic acetylcholine receptor M2
Description: Muscarinic acetylcholine receptor M2
Organism : Homo sapiens
P08172 ENSG00000181072
Protein: Muscarinic acetylcholine receptor M3
Description: Muscarinic acetylcholine receptor M3
Organism : Homo sapiens
P20309 ENSG00000133019
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Ion channel Voltage-gated ion channel Voltage-gated calcium channel
- 16100 - - -
Membrane receptor Family A G protein-coupled receptor Small molecule receptor (family A GPCR) Monoamine receptor Acetylcholine receptor
- - 40 1-2 -
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC22 family of organic cation and anion transporters
- - - - 76
Transporter Primary active transporter ATP-binding cassette ABCB subfamily
- 27400-27400 - - -
Assay Description Organism Bioactivity Reference
Affinity for rat Muscarinic acetylcholine receptor M2 Rattus norvegicus 6.97 nM
Affinity for rat Muscarinic acetylcholine receptor M3 Rattus norvegicus 0.95 nM
Binding affinity for rat cortex muscarinic acetylcholine receptor M1 using [3H]pirenzepine Rattus norvegicus 5.9 nM
Binding affinity for rat heart muscarinic acetylcholine receptor M2 using [3H]quinuclidinyl benzilate Rattus norvegicus 14.0 nM
Binding affinity for rat salivary gland muscarinic acetylcholine receptor M3 using [3H]N-methylscopolamine Rattus norvegicus 5.3 nM
Binding affinity to human muscarinic M3 receptor Homo sapiens 1.3 nM
Binding affinity to human muscarinic M2 receptor Homo sapiens 16.0 nM
Antagonism at muscarinic M2 receptor in isolated guinea pig urinary bladder Cavia porcellus 39.81 nM
Antagonism in muscarinic M3 receptor in guinea pig left atria Cavia porcellus 79.43 nM
Displacement of 1-[N-methyl- 3H]scopolamine from human muscarinic M1 receptor expressed in Sf9 cells Homo sapiens 1.0 nM
Displacement of 1-[N-methyl- 3H]scopolamine from human muscarinic M2 receptor expressed in Sf9 cells Homo sapiens 8.1 nM
Displacement of 1-[N-methyl- 3H]scopolamine from human muscarinic M3 receptor expressed in Sf9 cells Homo sapiens 0.78 nM
Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy Homo sapiens 75.7 %
DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine) None 3.518 nM DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine) None 0.847 nM
DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine) None 27.0 nM DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine) None 9.612 nM
DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine) None 2.71 nM DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine) None 0.574 nM
DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine) None 1.994 nM DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine) None 0.278 nM
DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine) None 3.222 nM DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine) None 2.315 nM
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide) None 792.0 nM DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide) None 504.0 nM
DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol) None 24.2 nM DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol) None 10.2 nM
DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil) Rattus norvegicus 820.3 nM
DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) None 600.0 nM
DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone) None 428.8 nM DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone) None 145.6 nM
DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55) None 85.5 nM DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55) None 67.9 nM
Displacement of [3H]N-methylscopolamine from human muscarinic M1 receptor expressed in CHO cells after 120 mins by scintillation counting Homo sapiens 2.399 nM
Displacement of [3H]N-methylscopolamine from human muscarinic M2 receptor expressed in CHO cells after 120 mins by scintillation counting Homo sapiens 11.75 nM
Displacement of [3H]N-methylscopolamine from human muscarinic M3 receptor expressed in CHO cells after 120 mins by scintillation counting Homo sapiens 1.514 nM
Displacement of [3H]N-methylscopolamine from human muscarinic M4 receptor expressed in CHO cells after 120 mins by scintillation counting Homo sapiens 3.631 nM
Displacement of [3H]N-methylscopolamine from human muscarinic M5 receptor expressed in CHO cells after 120 mins by scintillation counting Homo sapiens 14.13 nM
Inhibition of muscarinic acetylcholine receptor in rat cortex Rattus norvegicus 2.0 nM
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate Severe acute respiratory syndrome coronavirus 2 15.08 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 0.42 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 0.42 %

Related Entries

Cross References

Resources Reference
ChEBI 7856
ChEMBL CHEMBL1231
DrugBank DB01062
DrugCentral 2028
FDA SRS K9P6MC7092
Human Metabolome Database HMDB0015195
Guide to Pharmacology 359
KEGG C07360
PharmGKB PA164746030
PubChem 4634
SureChEMBL SCHEMBL2992
CONTENTS